North Plainfield, NJ, United States of America

James M Balkovec

This inventor holds 47 USPTO granted patents, plus 1 CIPO patent and 12 EPO patents, primarily in Glucocorticoid Modulators. Top assignees: Merck + Co., Inc., Merck Sharp + Dohme Corp., Mochida Pharmaceutical Co., Ltd.. Active years: 1992-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James M Balkovec. Retrieved from https://idiyas.com/inventor/james-m-balkovec

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 47

% Patents Active = 87.2

CIPO Patents = 1

EPO Patents = 12 (Patent Applications = 1)

Average Co-Inventor Count = 3.1

ph-index = 10

Forward Citations = 269(Granted Patents)

Location History:

N. Plainfield, NJ (US) (1994 - 1998)
North Plainfield, NJ (US) (1992 - 2001)
Martinsville, NJ (US) (2003 - 2018)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

3 out of 229

Mochida Pharmaceutical Co., Ltd.

5. 1 out of 834,708

Other

patents

where one patent can have more than one assignee

Years Active: 1992-2018

Loading Chart...

Areas of Expertise:

Glucocorticoid Receptor Modulators

Factor IXa Inhibitors

Antifungal Agents

Triazole Derivatives

Sordarin Derivatives

Cyclohexapeptidyl Compounds

Lipopeptide Compounds

Hydroxysteroid Dehydrogenase Inhibitors

Aza Cyclohexapeptide Compounds

Bacterial Infections

Diabetes Treatment

Obesity Treatment

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9914727 - Factor IXa inhibitors (2018-03-13),

2. 9708308 - Factor IXa inhibitors (2017-07-18),

3. 9695198 - Factor IXa inhibitors (2017-07-04),

4. 8222255 - Antifungal agents (2012-07-17),

5. 8178546 - Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 (2012-05-15),

6. 8026264 - Triazole derivatives as inhibitors of 11-β hydroxysteroid dehydrogenase-1 (2011-09-27),

7. 7981910 - Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1 (2011-07-19),

8. 7915252 - Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 (2011-03-29),

9. 7863465 - Antifungal agents (2011-01-04),

10. 7732432 - 17-carbamoyloxy cortisol derivatives as selective glucocorticoid receptor modulators (2010-06-08),

11. 7691887 - Triazole derivatives which are SMO antagonists (2010-04-06),

12. 7662846 - Selective spirocyclic glucocorticoid receptor modulators (2010-02-16),

13. 7625937 - 1H-benzo[F]indazol-5-YL derivatives as selective glucocorticoid receptor modulators (2009-12-01),

14. 7504402 - Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1 (2009-03-17),

15. 7329683 - 11-β-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia (2008-02-12),

Title: James M. Balkovec: Innovator in Factor IXa Inhibitors

Introduction

James M. Balkovec, a dedicated inventor from North Plainfield, NJ, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 47 patents, Balkovec's work primarily focuses on the development of compounds that target critical therapeutic areas.

Latest Patents

Among his most recent patents are the innovations surrounding Factor IXa inhibitors. The present inventions provide compounds of Formula (I) and pharmaceutical compositions that comprise these compounds. These developments are aimed at treating or preventing thromboses, embolisms, hypercoagulability, or fibrotic changes, showcasing Balkovec's commitment to advancing medical science and patient care.

Career Highlights

James M. Balkovec has had a distinguished career, having worked with renowned companies such as Merck & Company, Inc. and Merck Sharp & Dohme Corporation. His affiliations with these industry leaders have played a crucial role in fostering his innovative spirit and technical expertise.

Collaborations

Throughout his career, Balkovec has collaborated with notable colleagues, including Frances A. Bouffard and Donald W. Graham. These partnerships have contributed to the successful development of his patents and further highlight the importance of teamwork in scientific innovation.

Conclusion

James M. Balkovec's extensive patent portfolio and his pioneering work in Factor IXa inhibitors position him as a significant figure in the pharmaceutical industry. His dedication to innovation continues to pave the way for new therapeutic solutions, reflecting the profound impact of inventors on modern medicine.

Profile summary based on public USPTO records.